跳轉至內容
Merck
全部照片(1)

重要文件

18858

Supelco

5-氨基水杨酸

analytical standard

同義詞:

5-AS, 5-氨基-2-羟基苯甲酸, 氨水杨酸

登入查看組織和合約定價


About This Item

線性公式:
H2NC6H3-2-(OH)CO2H
CAS號碼:
分子量::
153.14
Beilstein:
2090421
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

analytical standard

品質等級

化驗

≥98.5% (NT)
≥99.0% (GC)

儲存期限

limited shelf life, expiry date on the label

技術

HPLC: suitable
gas chromatography (GC): suitable

雜質

≤0.5% water

mp

275-280 °C (dec.) (lit.)

應用

pharmaceutical

形式

neat

儲存溫度

2-8°C

SMILES 字串

Nc1ccc(O)c(c1)C(O)=O

InChI

1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

InChI 密鑰

KBOPZPXVLCULAV-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

應用

5-氨基水杨酸是适用于ELISA分析的过氧化物酶底物。这一底物产生可溶性的棕色终产物,可在450nm处通过分光光度法读取。使用3 N NaOH可终止反应并在550 nm处读取结果。
有关合适的仪器技术的更多信息,请参阅产品的分析证书。想要获得更多支持,请联系技术服务部。

象形圖

Exclamation mark

訊號詞

Warning

危險分類

Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

No data available

閃點(°C)

No data available


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Grzegorz Garbacz et al.
The Journal of pharmacy and pharmacology, 67(2), 199-208 (2015-01-06)
For the treatment of inflammatory bowel disease, the development of pH responsive modified release dosage forms is one of the most common approaches to achieve targeted drug delivery. In this study, the dissolution behaviour of eight different modified release (MR)
Rosario Cuomo et al.
United European gastroenterology journal, 2(5), 413-442 (2014-11-02)
The statements produced by the Consensus Conference on Diverticular Disease promoted by GRIMAD (Gruppo Italiano Malattia Diverticolare, Italian Group on Diverticular Diseases) are reported. Topics such as epidemiology, risk factors, diagnosis, medical and surgical treatment of diverticular disease (DD) in
W J Sandborn et al.
Alimentary pharmacology & therapeutics, 41(5), 409-418 (2015-01-16)
Conventional oral corticosteroids are effective at reducing inflammation associated with ulcerative colitis (UC); however, systemic adverse effects limit their use. Budesonide MMX is an extended-release, second-generation corticosteroid that targets delivery of budesonide to the entire colon. To analyse efficacy and
Natalia Pedersen et al.
Inflammatory bowel diseases, 20(12), 2276-2285 (2014-09-24)
To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course. Prospective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed
Alan C Moss et al.
The American journal of gastroenterology, 109(12), 1850-1855 (2014-06-11)
Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and predict those at risk for

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務